At the heart of this study lies c-Myc, a transcription factor long known for orchestrating a vast network of genes involved in cell growth, proliferation, and metabolism. Its dysregulation is a hallmark of many aggressive cancers. Yet, the precise downstream effectors through which c-Myc modulates the tumor microenvironment and cellular senescence remained obscure until now. Through rigorous experimentation, the authors demonstrate that c-Myc directly binds to regulatory elements within the CFL1 promoter region, facilitating its transcriptional upregulation. The elevated expression of cofilin-1 profoundly affects the cellular cytoskeleton, imparting structural remodeling that underpins altered cell motility and signaling.

Senescence, traditionally recognized as a permanent cell cycle arrest mechanism, serves as a crucial barrier against malignant transformation. However, senescent cells can paradoxically adopt a secretory phenotype that influences neighboring cells—a phenomenon known as the senescence-associated secretory phenotype (SASP). The current study reveals that lung cancer cells, upon c-Myc-mediated CFL1 activation, enter a senescence-like state characterized by morphological changes, altered gene expression, and secretion of factors that activate migration and proliferation programs in adjacent non-senescent cancer cells. This bystander effect suggests an intricate mode of tumor progression in which senescent cells, rather than halting cancer development, actively remodel the microenvironment to favor tumor growth and dissemination.

The significance of CFL1 in this context cannot be understated. Cofilin-1 is a pivotal regulator of actin dynamics, controlling filament turnover and cell motility. Overexpression of CFL1 has been observed in various malignancies with strong links to invasive phenotypes and poor prognosis. By establishing a direct regulatory connection between c-Myc and CFL1, the researchers have unveiled a critical axis that may be exploited therapeutically. Targeting this pathway could disrupt the dual roles of senescence-like cells in lung tumors—both as intrinsic growth-arrested cells and as promoters of malignant phenotypes in neighboring cells—potentially halting tumor expansion and metastasis.

Delving deeper into the mechanistic landscape, the study involved a combination of chromatin immunoprecipitation assays, gene expression analyses, and functional cell-based experiments. These approaches confirm not only the binding of c-Myc to the CFL1 promoter but also the functional consequence of this interaction evident in enhanced CFL1 transcription. Lung cancer cell lines engineered to overexpress c-Myc demonstrated marked increases in CFL1 levels, alongside classic markers of senescence such as SA-β-gal staining and upregulation of cell cycle inhibitors like p21. This senescence-like phenotype, rather than abrogating malignancy, serves as a nexus for potent paracrine signaling.

Perhaps one of the most striking insights from this research is the elucidation of how these senescence-like cells influence their microenvironment. Conditioned media from c-Myc/CFL1-upregulated cells robustly stimulated migration and proliferation in recipient lung cancer cells. This bystander effect underscores the complexity of tumor ecology, where cellular cross-talk mediated by secreted factors can reinforce aggressive phenotypes and therapeutic resistance. Such dynamics challenge the traditional view of senescence solely as a tumor suppressive mechanism and highlight the nuanced outcomes driven by oncogene-induced cellular programs.

Importantly, the implications stretch beyond lung cancer. The c-Myc-CFL1 axis may represent a conserved pathway in multiple tumor types where cofilin-1’s role in cytoskeletal regulation intersects with oncogenic signaling. This opens exciting avenues for broader oncological research, seeking small molecule inhibitors or biologics that can modulate cofilin activity or the c-Myc transcriptional network. Indeed, pharmacological disruption of this axis might not only attenuate tumor cell autonomous growth but also diminish pro-tumorigenic bystander interactions, offering a multipronged therapeutic strategy.

The team’s integration of advanced genomic and proteomic tools afforded a comprehensive portrayal of the pathway dynamics. RNA sequencing and proteomic profiling of lung cancer cells revealed downstream signaling cascades influenced by CFL1 upregulation, including pathways governing extracellular matrix remodeling, epithelial-mesenchymal transition (EMT), and resistance to apoptosis. These insights help contextualize how senescent cells contribute to a permissive niche for cancer dissemination.

Moreover, the study addresses long-standing questions concerning the “senescence paradox” observed in cancer biology. Traditionally posited as a tumor-suppressive endpoint, senescence paradoxically fuels tumor progression through SASP-mediated communication. By providing a tangible molecular basis for these phenomena grounded in c-Myc and CFL1, the research illuminates the dual nature of senescence and challenges therapeutic strategies aimed at simply inducing senescence without accounting for its complex downstream effects.

The translational impact extends into prognostic applications. Elevated cofilin-1 levels correlate with poor outcomes in lung cancer patients, suggesting that CFL1 could serve as a biomarker for aggressive disease subtypes. Combined with c-Myc expression profiling, such markers could refine patient stratification and enable personalized treatment approaches that consider the tumor microenvironment’s heterogeneity and dynamic nature.

Complementary in vivo experiments further reinforce the clinical relevance. Murine models bearing lung tumors with manipulated c-Myc and CFL1 expression displayed accelerated tumor growth and metastatic spread correlating with senescence-like cellular phenotypes and altered microenvironmental signatures. These preclinical data underscore the urgent need for therapeutic interventions targeting this newly uncovered axis.

As our understanding of cancer biology evolves into an appreciation of intercellular communications, the c-Myc-CFL1 mediated senescence-like program exemplifies the sophisticated strategies tumors employ to evade control and progress relentlessly. This research not only expands the molecular lexicon of oncogenic pathways but also challenges investigators and clinicians to conceptualize therapeutic designs that disrupt tumor ecosystems holistically rather than targeting isolated cellular mechanisms.

In conclusion, this pioneering work delineates a novel and impactful molecular circuitry by which c-Myc transactivates CFL1, triggering senescence-like phenotypes that paradoxically amplify bystander effects in lung cancer cells. This dual role intensifies cellular migration and proliferation, likely driving tumor aggressiveness and metastatic potential. The c-Myc/CFL1 axis emerges as a promising target for innovative therapies aimed at impeding both cell-autonomous and non-cell-autonomous facets of lung cancer pathology. Given the pressing global burden of lung cancer, such insights are vital stepping stones toward more effective, durable treatments that could transform patient outcomes worldwide.

Subject of Research:
This study examines how the oncogene c-Myc regulates CFL1 expression to induce a senescence-like phenotype that potentiates bystander effects enhancing migration and proliferation in lung cancer cells.

Article Title:
c-Myc transactivates CFL1 to induce senescence-like phenotype and potentiate the bystander effects for the migration and proliferation in lung cancer cells.

Article References:
Chou, YT., Leu, JD., Yang, WY., et al. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03065-3

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-026-03065-3

Lung cancer persists as the leading cause of cancer mortality globally, with NSCLC accounting for approximately 80 to 85 percent of all lung cancer cases. Despite continuous advancements in conventional treatments such as surgery, chemotherapy, radiation, and targeted therapy, many patients ultimately develop resistance, significantly diminishing the efficacy of these interventions and adversely affecting survival outcomes. Finding novel targets to reverse or circumvent this resistance is thus a critical priority in current cancer research.

Central to this study was the examination of the growth hormone (GH) pathway, traditionally known for its regulatory roles in growth, metabolism, and development. GH exerts its biological effects by binding to the growth hormone receptor (GHR), a transmembrane protein that activates intracellular signaling cascades upon ligand engagement. Emerging evidence suggests aberrant expression and activation of GH and GHR can contribute to oncogenesis and tumor progression, but their impact on lung cancer, particularly in the context of drug resistance, has been inadequately understood.

Employing comprehensive bioinformatic analyses on extensive patient datasets, including genomic and transcriptomic data from The Cancer Genome Atlas (TCGA), the research team compared GHR expression levels in tumor samples relative to normal lung tissue. The results revealed a pronounced overexpression of GHR in NSCLC tumors, highlighting a potential oncogenic role of GH signaling in lung carcinogenesis. This overexpression was not merely a biomarker but correlated directly with clinical outcomes.

The survival analysis conducted as part of the study was particularly striking: patients with tumors exhibiting high GHR expression had markedly shorter overall survival, with median survival times plummeting to between 36 and 40 months. In contrast, those with tumors expressing low levels of GHR had a median survival of roughly 66 months. This stark difference underscores a robust prognostic significance of GHR and signals its potential as a therapeutic target.

In vitro experiments further elucidated the mechanisms behind GH-induced therapy resistance. When human and mouse lung cancer cells were exposed to growth hormone, they demonstrated increased resistance to chemotherapy agents such as doxorubicin and cisplatin, drugs commonly employed in lung cancer treatment protocols. This resistance was mechanistically linked to enhanced activity of drug-efflux pumps—protein complexes that actively transport chemotherapeutic compounds out of cancer cells, thereby reducing intracellular drug concentrations and efficacy.

Moreover, GH exposure induced cellular changes associated with enhanced metastatic potential and reduced apoptosis. These alterations included modifications in signaling pathways that regulate epithelial-mesenchymal transition and cell survival. Collectively, these findings illustrate how GH signaling confers a more aggressive phenotype to lung cancer cells that not only withstand chemotherapeutic assault but also exhibit increased capacity for tumor spread.

To explore therapeutic avenues, the study investigated the efficacy of pegvisomant, a GH receptor antagonist approved by the FDA for the treatment of acromegaly, a disorder characterized by excessive GH production. Pegvisomant binds to GHR, blocking its activation and subsequent downstream signaling. Notably, the drug was discovered by John J. Kopchick, the lead investigator, decades ago, highlighting a scientific journey bridging fundamental discovery and clinical application.

Laboratory assays demonstrated that pegvisomant effectively counteracted the pro-survival and drug-resistant effects induced by GH in lung cancer cells. Importantly, when pegvisomant was combined with chemotherapy, cancer cells exhibited heightened sensitivity to the drugs, allowing effective tumor cell killing at lower chemotherapeutic doses. This potentiation suggests that GHR blockade may synergistically enhance existing treatment regimens while potentially mitigating chemotherapy-associated toxicity.

Despite the promising laboratory results and compelling correlation with clinical data, the study emphasizes the current limitations and requisite next steps. All findings to date are derived from computational analysis of patient data and experiments in cultured cell lines; in vivo validation remains essential. Encouragingly, prior animal studies conducted by the team and collaborators demonstrated significant therapeutic benefits of combining pegvisomant with standard therapies in mouse models of melanoma, pancreatic, and liver cancers. The forthcoming phase involves applying these approaches to NSCLC mouse models to evaluate efficacy and safety profiles in a complex biological system.

If preclinical studies yield positive results, they will pave the way for clinical trials designed to assess whether targeting GHR can safely and effectively overcome drug resistance in lung cancer patients. Such trials will be critical to ascertain the translational potential and clinical utility of this novel therapeutic strategy.

The study represents a collaborative effort among Ohio University’s Institute for Molecular Medicine and the Aging, the Diabetes Institute, the Translational Biomedical Sciences Program, and departmental divisions of Biomedical and Biological Sciences. International cooperation was also integral, incorporating expertise from Erasmus Medical Centre in the Netherlands, underscoring the global commitment to overcoming the challenges posed by lung cancer.

This innovative research advances our understanding of growth hormone’s paradoxical role in cancer biology and opens new investigative pathways in the quest to enhance pulmonary oncology outcomes. The evidence positions GHR not only as a biomarker of poor prognosis but as a modifiable target that could revolutionize lung cancer treatment by overcoming one of its greatest obstacles: therapy resistance.

Subject of Research: Cells

Article Title: Targeting Growth Hormone Receptor to Overcome Therapy Resistance in Non-Small Cell Lung Cancer

News Publication Date: 22-Dec-2025

Web References: https://www.mdpi.com/1422-0067/27/1/115

Keywords: Growth hormone, Lung cancer, Cells, Cancer cells, Drug interactions, Drug studies, Drug resistance